Proactive - Interviews for investors

Imugene Ltd (ASX:IMU, OTC:IUGNF) managing director and CEO Leslie Chong and strategic advisor Dr Yuman Fong sit down with Proactive’s Jonathan Jackson to discuss Professor Fong’s expertise and the latest company developments.

Dr Fong is a world-renowned cancer researcher, physician and surgeon whose clinical work has focused on OV for more than 30 years. He is the inventor of OV CF33.

Imugene has dosed the first patient in its trial for bile tract cancer (cholangiocarcinoma) patients. The MAST (metastatic advanced solid tumours) Phase 1 trial has been expanded due to early responses in gastrointestinal cancers, particularly cholangiocarcinoma, using Imugene’s cancer-killing virus CF33, known as VAXINIA. The trial, held at St Vincent’s Hospital, Melbourne, Australia, expects to enrol 10 patients.

Interim results showed positive responses in gastrointestinal cancers, including a complete response in bile tract cancer. The trial's fifth cohort of both arms has cleared and the sixth high-dose cohort is now open.

Chong expressed optimism about VAXINIA's potential in bile tract cancer, highlighting the trial's advancement to higher doses to gather key data. In November 2023, the US FDA granted fast-track designation to VAXINIA MAST for bile tract cancer, enabling closer cooperation to expedite the approval process.

Bile tract cancer is a rare and challenging disease, often responding poorly to immunotherapy. A recent study reported a complete response in a patient after receiving a mid-dose of IT-administered VAXINIA monotherapy, with no safety signals observed. The Phase 1 MAST trial has progressed through monotherapy dose escalation cohorts and includes a combination study with pembrolizumab. The CF33 virus, developed by City of Hope, has shown preclinical effectiveness in shrinking various cancer tumours.

#ProactiveInvestors #Imugene #ASX #OTC #CancerResearch, #BileTractCancer, #Cholangiocarcinoma, #VAXINIA, #Oncology, #ClinicalTrial, #MASTTrial, #FDAFastTrack, #InnovativeTreatment, #GastrointestinalCancer, #CancerTreatment, #LeslieChong, #StVincentsHospital, #Melbourne, #Immunotherapy, #CheckpointInhibitor, #Pembrolizumab, #CF33Virus, #CityOfHope

#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Cynata Therapeutics Ltd (ASX:CYP) CEO and managing director Dr Kilian Kelly is in the Proactive studio following the 18th annual Bioshares Biotech Summit in Perth.

Cynata is an Australian stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™, using discoveries made at the University of Wisconsin-Madison (UWM).

UWM is a world-renowned leader in stem cell research, in particular for the work by Professor James Thomson’s group, which included the first successful isolation of human embryonic stem cells in 1998 and the derivation of induced pluripotent stem cells (iPSCs) from human adult cells in 2007. Professor Igor Slukvin, a co-founder of Cynata, was also a member of the team that conducted UWM’s pioneering iPSC research.

The Cymerus technology has several characteristics which makes it ideal for the development of cell-based therapeutics. Most critically, the Cymerus manufacturing process ensures that cells for therapeutic use can be produced in virtually limitless quantities. This means that Cynata will not have to constantly seek out fresh stem cell donors to fuel its manufacturing demands.

This has the potential to create a new standard in the emergent arena of regenerative medicine and stem cell therapeutics and provides Cynata with both a unique differentiator and an important competitive position.

#ProactiveInvestors #CynataTherapeutics #ASX #CYP #Biotech #Bioshares #Summit #BiosharesBiotechSummit #StemCell

#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Dimerix Ltd (ASX:DXB) CEO and managing director Dr Nina Webster is in the Proactive studio following the 18th annual Bioshares Biotech Summit in Perth.

Dimerix is is a clinical stage biopharmaceutical company with a scalable, proprietary platform technology called Receptor-HIT. Incorporated in 2004, Dimerix develops and commercialises patient preferred pharmaceutical products for global markets using its innovative receptor technology to identify and develop drugs in areas with an unmet need.

Dimerix has successfully used the Receptor-HIT technology to identify a novel treatment (DMX-200) that may transform the lives of patients with inflammatory diseases, such as kidney or lung diseases. Dimerix encourages collaboration and is well positioned to discuss partnering and product development.

#ProactiveInvestors #Dimerix #ASX #DXB #Biotech #Bioshares #Summit #BiosharesBiotechSummit

#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Acrux Ltd (ASX:ACR) CEO and managing director Michael Kotsanis is in the Proactive studio following the 18th annual Bioshares Biotech Summit in Perth.

Acrux is a specialty pharma company with a successful track record of developing and commercialising a pipeline of topically applied pharmaceutical products.

Drawing on 25 years of experience, Acrux has marketed through licensees a number of products worldwide with emphasis on the United States. Acrux is formulating and developing a range of topical generic products to bring affordable products to market. Acrux encourages collaboration and is positioned to discuss commercial partnering and product development opportunities.

_#ProactiveInvestors #Acrux #ASX #ACR #Biotech #Bioshares #Summit #BiosharesBiotechSummit

#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

LBT Innovations Ltd (ASX:LBT) CEO and managing director Brent Barnes is in the Proactive studio following the 18th annual Bioshares Biotech Summit in Perth.

LBT describes itself as a groundbreaking designer of advanced technology solutions for the medical industry. The biotech specialises in bringing advanced medical technologies to market and its core capabilities include artificial intelligence, image analysis and software engineering solutions that improve medical diagnostic workflows.

The company’s first technology was an automated culture plate streaking system called MicroStreak. It was brought to market as the PREVI® Isola and initiated a new era in automation for clinical laboratories.

#ProactiveInvestors #LBTInnovations #ASX #LBT #Biotech #Bioshares #Summit #BiosharesBiotechSummit

#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Spectra Systems Corporation CEO Nabil Lawandy joined Steve Darling from Proactive to share exciting news about the company’s latest achievement. Spectra Systems has secured a substantial contract valued at $37.9 million to manufacture sensors for an existing central bank customer. An additional tranche of $1.7 million is expected later this year upon the signing of the related manufacturing contract. This will bring the total sensor manufacturing revenues from the new contract to $39.6 million.

Lawandy explained that revenue recognition for this contract will follow a standard cost accounting basis, with certain progress milestones related to expenditures. The bulk of the revenues from this contract are anticipated to be received from the first quarter of 2025 through the fourth quarter of 2027, with trailing manufacturing contract revenues of approximately $4.5 million extending until 2029.

This manufacturing contract is expected to generate profits significantly higher than previously estimated over its term. The increased margins highlight the strong financial performance and strategic importance of this contract for Spectra Systems.

Lawandy emphasized the significance of this contract, noting that it strengthens Spectra Systems’ position in the market and underscores the company’s capability to deliver high-quality sensor solutions to major clients. This deal is a testament to Spectra Systems’ commitment to innovation and excellence in sensor manufacturing, providing critical technology for central banking operations.

The long-term nature of this contract also ensures a steady revenue stream for Spectra Systems, supporting its growth and profitability goals. With this new contract, Spectra Systems is well-positioned to continue its trajectory of success and deliver exceptional value to its stakeholders.

Spectra Systems remains dedicated to advancing its technological capabilities and expanding its market reach, solidifying its reputation as a leader in sensor manufacturing and related technologies.

#proactiveinvestors #spectrasystemscorporations #aim #spsy #otc sctq

#NabilLawandy, #CentralBankContract, #SensorManufacturing, #TechDevelopment, #FinancialGrowth, #OrganicDevelopments, #ContinuousInkjet, #CovertInks, #SmartphoneAuthentication, #PolymerSecurity, #CartorSecurityPrinters, #StrategicAcquisitions, #RevenueGrowth, #Innovation, #SecurityFeatures, #TechIndustry, #LongTermProfit, #BusinessExpansion, #CorporateFinance#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Aclara Resources Chief Executive Officer Ramon Barua joined Steve Darling from Proactive to share significant news about the company’s strategic initiatives. Aclara Resources has signed a Memorandum of Understanding (MOU) with VACUUMSCHMELZE GmbH & Co (VAC). This MOU establishes a non-binding, non-exclusive, preliminary agreement for the two companies to jointly approach potential clients with a comprehensive "mine-to-magnets" solution for ESG-compliant permanent magnets.

During the interview, Barua emphasized that Aclara and VAC see a significant market opportunity driven by the rising demand for electric vehicles (EVs), wind turbines, and other clean technologies. These sectors require rare earth permanent magnets, which must meet increasingly stringent ESG standards. Permanent magnets are essential components in these technologies, requiring significant quantities of both light and heavy rare earth minerals.

Currently, the market for these rare earth minerals and the industrial capacity to process them into permanent magnets is limited, with supply concentrated among a few Asia-based suppliers. This supply and demand dynamic presents a promising opportunity to develop a new, resilient, and ESG-focused supply chain for permanent magnets. The strategic alliance between VAC and Aclara is particularly noteworthy due to Aclara's position as one of the few potential suppliers of Dysprosium and Terbium. These two highly sought-after heavy rare earth minerals are critical for the production of permanent magnets and are not easily available outside of Asia.

Aclara is actively developing two ionic clay projects in Chile and Brazil, which are focused on producing high-purity heavy rare earth carbonate. Additionally, the company is advancing its processing technology through its US-based subsidiary. This technology will enable Aclara to process the carbonate into magnetic alloys, which are the essential inputs required by VAC to produce permanent magnets.

Barua expressed optimism about this strategic alliance, highlighting its potential to create a robust and sustainable supply chain for rare earth permanent magnets. This collaboration aligns with Aclara’s commitment to sustainability and innovation, positioning the company to meet the growing global demand for environmentally responsible and high-performance permanent magnets.

With this partnership, Aclara Resources and VAC aim to contribute significantly to the advancement of clean technologies and the broader goal of reducing the carbon footprint of essential industries.

#proactiveinvestors #aclararesourcesinc #tsx #ara #mining #rareearths

#ElectricVehicles #MagnetProduction #AutomotiveIndustry #SupplyChain #SustainableMaterials #USManufacturing #EuropeanMarket #OEM #GeneralMotors #VacuumMagnets #MiningIndustry #Chile #Brazil #NorthAmerica #EnvironmentalSustainability #Partnership #TechnologyIntegration #EVComponents #RenewableEnergy

#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Ocean Power Technologies (OPT), a leader in innovative ocean energy solutions, has secured a significant new contract for the immediate delivery of a PowerBuoy equipped with Merrows, its cutting-edge Artificial Intelligence capable Maritime Domain Awareness Solution. CEO Philipp Stratmann shared this exciting news with Steve Darling from Proactive, highlighting that this contract, focused on deployment in the Middle East, is set to generate revenues within the current quarter.

In his discussion with Steve Darling from Proactive, Stratmann emphasized that this achievement builds on the company’s previous announcement of its selection as a preferred supplier for its Merrows-equipped buoys in the region. This new revenue-generating contract underscores OPT’s continued business growth across all its product lines, including WAM-Vs (Wave Adaptive Modular Vessels) and PowerBuoys.

Stratmann elaborated on the strategic importance of this shipment, which features a solar and wind-powered system. He noted that it demonstrates OPT’s capability to provide robust and versatile solutions capable of servicing a wide range of marine environments globally. The deployment of this AI-enhanced PowerBuoy not only strengthens OPT's presence in the Middle East but also exemplifies its commitment to delivering advanced maritime technology solutions worldwide.

#proactiveinvestors #oceanpowertechnologiesinc #nyseamerican #optt

#MaritimeDomainAwareness, #RenewableEnergy, #SolarEnergy, #WindEnergy, #MiddleEast, #OffshoreEnergy, #MaritimeSecurity, #Commercialization, #Innovation, #BuoyTechnology, #MarineSolutions, #EnergyTech, #OPTNews, #GreenEnergy, #SecuritySolutions, #EnergyContracts, #TechDeployment, #EnvironmentalTechnology, #SustainableTech#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Lumos Diagnostics CEO Doug Ward joined Steve Darling from Proactive to share significant updates about the company’s progress and expansion. Lumos Diagnostics specializes in providing rapid, cost-effective, and comprehensive point-of-care diagnostic test solutions, aiding healthcare professionals in accurately diagnosing and managing medical conditions. The company also offers customized assay development and manufacturing services for point-of-care tests, along with proprietary digital reader platforms.

Ward announced that Lumos Diagnostics has extended its agreement with Henry Schein Europe, which will now expand the distribution of its flagship product, FebriDx®, into Belgium. Henry Schein, Inc., the world’s largest provider of healthcare solutions to office-based dental and medical practitioners, currently distributes the FebriDx test in the UK, Spain, Portugal, the Netherlands, and the US. Henry Schein’s Medical business entered the Belgian market in 2023, specifically targeting general practitioners and midwives.

In addition to the European expansion, Ward shared that FebriDx is now available to healthcare practitioners in Australia and New Zealand. This follows the signing of a distribution agreement with Regional Health Care Group, a Henry Schein company in Australia and New Zealand. FebriDx® is a rapid point-of-care test designed to differentiate viral from bacterial acute respiratory infections. The test delivers results within 10 minutes from a fingerstick blood sample, enabling healthcare providers to quickly and accurately manage infectious patients in various settings, including Primary Care, Urgent Care, Emergency Departments, Paediatrics, and other Outpatient environments.

Ward expressed enthusiasm about these new agreements, highlighting the importance of rapid diagnostic tools in improving patient care and outcomes. The expanded distribution agreements underscore Lumos Diagnostics' commitment to broadening its market presence and making its innovative diagnostic solutions accessible to more healthcare professionals worldwide.

These strategic moves position Lumos Diagnostics to significantly impact the global healthcare landscape by providing essential tools for the rapid and accurate diagnosis of infectious diseases. The company continues to focus on innovation, quality, and expanding its reach to meet the growing demand for effective point-of-care diagnostic solutions.

#proactiveinvestors #lumosdiagnostics

#MedicalDiagnostics, #HealthcareInnovation, #LateralFlowTests, #COVID19Testing, #FDAApproval, #GlobalHealthcare, #MedicalTechnology, #PatientCare, #AntibioticResistance, #FiberxTest, #HealthcareGrowth, #MedicalResearch, #DiagnosticsMarket, #HealthcareDistribution, #MedicalPartnerships, #DiagnosticTests, #HealthcareSolutions, #InfectionTesting, #ElectronicHealthRecords

#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Nextech3D.ai CEO Evan Gappelberg joined Steve Darling from Proactive to announce that the company has achieved certification as a Certified 3D Model External Content Provider for Amazon. This prestigious designation highlights Nextech3D.AI's outstanding technical expertise and leadership in the 3D platforms sector.

Amazon listings featuring 3D models have demonstrated an average twofold improvement in purchase conversions, presenting a high return on investment (ROI) that motivates more sellers to adopt 3D models. As an officially recognized 3D Model External Content Provider for Amazon, Nextech3D.ai is strategically positioned to capitalize on this substantial growth opportunity. Over the past five years, Nextech3D.ai has successfully delivered nearly 100,000 3D models and millions of augmented reality (AR) experiences to hundreds of clients.

Nextech3D.ai's patented technology for generating 3D models from 2D and CAD images enables the company to scale the creation of 3D models efficiently. This capability now allows Amazon sellers to publish their 3D models directly to Amazon's stores through a unified platform and team. As an Amazon 3D Model External Content Provider, Nextech3D.ai is offering its advanced 3D modeling solutions to Amazon's vast marketplace, supporting sellers in enhancing their product listings with immersive 3D models.

Gappelberg emphasized that this certification not only validates Nextech3D.ai's technical prowess but also opens new avenues for growth and innovation. The company's ability to streamline the 3D model creation process for Amazon sellers is expected to significantly boost their product visibility and sales on the platform. Nextech3D.ai's commitment to leveraging cutting-edge technology to provide top-tier 3D modeling solutions underscores its leadership in the industry and its dedication to driving tangible results for its clients.

With this new certification, Nextech3D.ai is well-positioned to expand its reach and impact in the e-commerce space, offering innovative solutions that enhance the shopping experience for consumers and drive business growth for sellers.

#proactiveinvestors #nextech3d.ai #cse #NTAR #otcqb #metaverse #toggle3D #ai

#AmazonCertification #3DModeling #GenerativeAI #TechNews #ECommerce #AmazonPrimeDay #BusinessGrowth #SKUs #AmazonBasics #SalesBoost #ConversionRate #DigitalInnovation #TechIntegration #AmazonSellers #FutureOfECommerce #3DTechnology #ProductModeling #AIModels#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews